{"id":"tak-019","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL3545328","moleculeType":"Small molecule","molecularWeight":"444.54"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"TAK-019 is an investigational personalized neoantigen vaccine that is engineered to target patient-specific mutations in tumor cells. It works by priming the immune system to recognize and attack cancer cells bearing these neoantigens, potentially enhancing anti-tumor immunity when combined with checkpoint inhibitors or other immunotherapies.","oneSentence":"TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:37:21.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Melanoma (in combination with checkpoint inhibitors)"},{"name":"Non-small cell lung cancer (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT05299359","phase":"PHASE3","title":"A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19)","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-04-15","conditions":"Coronavirus Disease (COVID-19)","enrollment":150},{"nctId":"NCT04712110","phase":"PHASE1, PHASE2","title":"A Study of TAK-019 in Healthy Japanese Adults (COVID-19)","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-02-12","conditions":"Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TAK-019","genericName":"TAK-019","companyName":"Takeda","companyId":"takeda","modality":"Biologic","firstApprovalDate":"","aiSummary":"TAK-019 is a therapeutic vaccine designed to stimulate immune responses against cancer cells expressing specific tumor-associated antigens. Used for Melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}